{"id":294978,"date":"2026-02-24T00:00:00","date_gmt":"2026-02-24T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0009-2024-biopharma-breast-cancer-current-treatment-current-treatment-physician-insights\/"},"modified":"2026-04-14T10:10:30","modified_gmt":"2026-04-14T10:10:30","slug":"cutron0009-2026-biopharma-breast-cancer-current-treatment-current-treatment-physician-insights-breast-cancer-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0009-2026-biopharma-breast-cancer-current-treatment-current-treatment-physician-insights-breast-cancer-us\/","title":{"rendered":"Breast Cancer &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; Breast Cancer (US)"},"content":{"rendered":"<p class=\"text-align-left\">The breast cancer treatment landscape is rapidly evolving. <abbr title=\"cyclin-dependent kinase 4\">CDK4<\/abbr>\/6 inhibitors (Pfizer\u2019s Ibrance, Novartis\u2019s Kisqali, and Eli Lilly\u2019s Verzenio) combined with endocrine therapy, are established as first-line treatment options for metastatic <abbr title=\"hormone receptor\">HR<\/abbr>positive \/ <abbr title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>-negative disease and have now expanded into the earlystage setting. Biomarker-driven therapies\u2014including Menarini Group\u2019s Orserdu (<i>ESR1<\/i>-mutant), Novartis\u2019s Piqray and Roche \/ Chugai Pharmaceutical\u2019s Itovebi (<i><abbr title=\"phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform\">PIK3CA<\/abbr><\/i>-mutant) and AstraZeneca\u2019s Truqap (<i><abbr title=\"phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform\">PIK3CA<\/abbr> \/ AKT1 \/ <\/i><i><abbr title=\"phosphatase and tensin\u00a0homolog\">PTEN<\/abbr><\/i>-mutant)\u2014have expanded treatment options for metastatic <abbr title=\"hormone receptor\">HR<\/abbr>-positive \/ <abbr title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>-negative disease. Meanwhile, Merck &#038; Co.\u2019s Keytruda has reshaped the treatment paradigm for certain patients with early and metastatic triple-negative breast cancer. <abbr title=\"poly ADP (adenosine diphosphate)-ribose polymerase\">PARP<\/abbr> inhibitors (AstraZeneca \/ Merck &#038; Co.\u2019s Lynparza and Pfizer\u2019s Talzenna) offer options for <i><abbr title=\"poly ADP (adenosine diphosphate)-ribose polymerase\">PARP<\/abbr><\/i>-mutant patients with either triple-negative or <abbr title=\"hormone receptor\">HR<\/abbr>-positive \/ <abbr title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>-negative disease. Next-generation <abbr title=\"antibody drug conjugate\">ADC<\/abbr>s (Gilead\u2019s Trodelvy, AstraZeneca \/ Daiichi Sankyo\u2019s Datroway, and Daiichi Sankyo \/ AstraZeneca\u2019s Enhertu for <abbr title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>low and <abbr title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>ultralow disease) have diversified therapy options for metastatic patients. In the <abbr title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>-positive metastatic setting, Enhertu\u00b4s label expansion into the second line is redefining treatment.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the treatment rates for breast cancer by key subtype and line of therapy?<\/li>\n<li>What are physician-reported testing rates for select biomarkers (e.g., mutations in <i><abbr title=\"phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform\">PIK3CA<\/abbr><\/i>, <i>ESR1, <\/i>and<i> <abbr title=\"poly ADP (adenosine diphosphate)-ribose polymerase\">PARP<\/abbr>, <\/i><abbr title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>-low \/ <abbr title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>-ultralow status, and <abbr title=\"programmed death-ligand 1\">PD-L1<\/abbr> expression) in relevant breast cancer subtypes?<\/li>\n<li>What is the patient share of key drugs and regimens by type of breast cancer?<\/li>\n<li>What are the main drivers of and key obstacles to the uptake of select therapies?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand the treatment landscape for a disease and how physicians make prescribing decisions.<\/li>\n<li>Evaluate the drivers and obstacles that influence treatment selection.<\/li>\n<li>Analyze your brand\u2019s performance from the physician perspective to enhance or defend your competitive position.<\/li>\n<\/ul>\n<p><strong>Primary research:\u00a0<\/strong>Survey of 100 medical oncologists in the United States fielded in December 2025.<\/p>\n<p><strong>Key drugs:\u00a0<\/strong>Ibrance, Kisqali, Verzenio, Lynparza, Talzenna, Piqray, Truqap, Itovebi, Orserdu, Enhertu, Trodelvy, Datroway, Phesgo, Keytruda.<\/p>\n","protected":false},"template":"","class_list":["post-294978","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-breast-cancer","biopharma-therapy-areas-solid-tumors","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/294978","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/294978\/revisions"}],"predecessor-version":[{"id":575191,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/294978\/revisions\/575191"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=294978"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}